In This Section
Fact Sheet: Molecular Imaging and Alzheimer's Disease
Download Printer Friendly Version
In 2023, the FDA approved Leqembi (lecanemab), a monoclonal antibody that targets and helps eliminate beta amyloid, a protein that builds up in the brains of individuals with Alzheimer’s disease. Studies showed the drug slowed the rate of cognitive and functional decline by 27%.
According to the Alzheimer’s Association, an estimated 6.7 million Americans age 65 or older are living with Alzheimer’s dementia in 2023. The number and proportion of Americans with Alzheimer’s or other dementias is expected to continue to grow in coming years because the risk of dementia increases with advancing age. The population of Americans age 65 and older is projected to grow to 88 million by 2050. Seventy-three percent of those currently living with AD are age 75 or older. Out of the total U.S. population, one in 9 people (10.8%) age 65 and older has Alzheimer’s dementia. The percentage of people with Alzheimer’s dementia increases with age: 5% are age 65-74, 13.1% are age 75-84, and 33.3% of people age 85 and older have Alzheimer’s dementia.
People younger than 65 can also develop Alzheimer's dementia, but it is much less common and prevalence is uncertain. Researchers believe about 110 of every 100,000 people ages 30-64 years, or about 200,000 Americans in total, have younger-onset dementia.
In AD, there is abnormal build-up of two proteins, amyloid and tau. Amyloid accumulates as plaques and tau as neurofibrillary tangles. Abnormal build-up of these proteins causes the neurons to work less efficiently. There is progressive damage to the neurons and connections between neurons, leading eventually to neuronal death. This process gradually spreads to the brain’s learning and memory center, the hippocampus, and then to other areas of the brain. Scientists believe these brain changes begin 10-20 years before the signs or symptoms of the disease appear. Common brain imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) scans cannot see amyloid plaques and neurofibrillary tangles. Molecular imaging provides the unique opportunity to visualize each of these characteristic features of Alzheimer's disease.
What is molecular imaging?
Molecular imaging is a type of medical imaging that provides detailed pictures of what is happening inside the body at the molecular and cellular level. While other kinds of diagnostic imaging procedures, such as x-rays, computed tomography (CT) and ultrasound create anatomical pictures, molecular imaging allows physicians to see physiology and function.
Molecular imaging offers unique insights into the human body that enable physicians to personalize patient care. In terms of diagnosis, molecular imaging is able to:
- provide information that is unattainable with other imaging technologies or that would require more invasive procedures such as biopsy or surgery
- identify disease in its earliest stages, often before symptoms occur or abnormalities can be detected with other diagnostic tests
As a tool for evaluating and managing the care of patients, molecular imaging studies help physicians:
- assess the function of nerves or brain tissue that have become abnormal in AD, Parkinson's disease, and other neurodegenerative diseases
- optimize treatment regimen
Molecular imaging procedures are noninvasive, safe and painless.
How does molecular imaging work?
When disease occurs, the biochemical activity of cells begins to change. For example, cancer cells multiply at a much faster rate and are more active than normal cells. Brain cells affected by dementia consume less energy than normal brain cells. Heart cells deprived of adequate blood flow begin to die.
As disease progresses, this abnormal cellular activity begins to affect body tissue and structures, causing anatomical changes that may be seen on CT or MRI scans. For example, cancer cells may form a mass or tumor. With the loss of brain cells, overall brain volume may decrease or affected parts of the brain may appear different in density than the normal areas. Similarly, the heart muscle cells that are affected stop contracting and the overall heart function deteriorates.
Molecular imaging excels at detecting the small, cellular changes that occur early in the course of disease, often well before structural changes can be seen on CT and MR images. Molecular imaging can detect abnormalities in the brain months or years before the structural changes might occur.
Most molecular imaging procedures involve an imaging device and an imaging agent, or probe. A variety of imaging agents are used to visualize cellular activity, such as the chemical processes involved in metabolism, oxygen use or blood flow. In nuclear medicine, which is a branch of molecular imaging, the imaging agent is a radiotracer, a compound that includes a radioactive atom, or isotope. Other molecular imaging modalities, such as optical imaging and molecular ultrasound, use a variety of different agents. Magnetic resonance spectroscopy is able to measure certain chemical levels in the body, without the use of an imaging agent.
Once the imaging agent is introduced into the body, it accumulates in a target organ or attaches to specific cells. The imaging device detects the imaging agent and creates pictures that show how it is distributed in the body. This distribution pattern helps physicians discern how well organs and tissues are functioning.
What molecular imaging technologies are used for Alzheimer’s disease?
Diagnosis of AD is currently a complex process that may include a detailed patient history, physical and neurological exams, laboratory tests and a lengthy process of excluding other possible causes of mental decline. Clinical diagnosis of AD has an accuracy of only 63% and tests, such as Draw a Clock, only become positive late in the disease process when little can be done to treat AD (Henderson, 2012). While a definitive diagnosis of AD is still only possible by autopsy following a patient's death, new diagnostic criteria from the Alzheimer's Association emphasize the importance of biomarkers, such as molecular neuroimaging.
Researchers are exploring how improved quantitative analysis and new molecular markers can help physicians diagnose AD earlier and more accurately. This, in turn, could improve patient management and outcomes.
What is PET?
Positron emission tomography (PET) involves the use of an imaging device (PET scanner) and a radiotracer that is injected into the patient’s bloodstream. A frequently used PET radiotracer in evaluating dementia is 18F-fluorodeoxyglucose (FDG), a compound derived from a simple sugar and a small amount of radioactive fluorine. More active brain cells accumulate more FDG tracer. The diagnostic accuracy of FDG PET scans for AD is 93% (Bohnen et. al., 2012). FDG PET also allows the differentiation of AD from other forms of dementia.
Amyloid PET uses a radiotracer that selectively labels amyloid plaques, which accumulate in AD (Johnson et. al, 2013). Below age 60, a positive amyloid PET is highly predictive of AD. A negative amyloid PET in a patient with dementia symptoms is highly predictive of some other form of dementia. However, over the age of 60, there may be a 20% or more false positive rate (Henderson, 2012; Johnson et. al, 2013). Therefore, the information from imaging should always be interpreted in conjunction with other testing and clinical assessment.
Regardless of the PET tracer used, once the radiotracer accumulates in the brain, it's natural decay eventually produces photons, small packets of light energy. The PET scanner is able to detect these photons and uses them to create three-dimensional images that show where the radiotracer is distributed in the body.
For details on when to use amyloid PET imaging to detect Alzheimer's, go to, Amyloid Brain Imaging Infographic.
This PET scan compares images from a control group patient without Alzheimer's disease (NC), a patient with Alzheimer's disease without depression (AD-n), and a patient with depressive Alzheimer's disease (AD-d). Figure A shows the midbrain, Fig. B shows the putamen, and Fig. C shows the thalamus. The color scale denotes the magnitude of tissue-to-cerebellum ratio. Serotonin levels in both Alzheimer's disease patients were lower than the control group patient. Source: http://jnm.snmjournals.org/content/50/8/1260.full
What is SPECT?
Single photon emission tomography (SPECT) involves the use of an imaging device (SPECT scanner) and a radiotracer that is injected into the patient's bloodstream. In perfusion SPECT imaging, the tracer accumulates in cells based on how much blood flow they receive. Since blood flow is correlate of activity in the brain, SPECT show areas of increased and decreased brain activity. Perfusion SPECT can demonstrate decreases of function in the temporal lobes, parietal lobes, and postural cingulate gyrus, consistent with AD and provides a reliable means of separating AD from other types of dementia.
Regardless of the SPECT tracer used, once the radiotracer accumulates in the brain, it's natural decay eventually produces gamma photons. The SPECT scanner, which is able to detect these gamma photons, creates three-dimensional images that show how the radiotracer is distributed in the brain.
PET and SPECT scanners are often combined with CT that produces detailed views of the anatomy. The combination of two imaging techniques-called co-registration, fusion imaging or hybrid imaging-allows information from two different kinds of scans to be viewed in a single set of images. CT imaging uses advances x-ray equipment and in some cases contrast-enhancing material to produce three-dimensional images.
How is PET and SPECT performed?
The procedure begins with an intravenous (IV) injection of a radiotracer. Then time is allowed for the tracer to distribute throughout the body. In the case of FDG, this can be between 30 and 60 minutes. In the case of perfusion SPECT, the tracer captures the image of the brain function in 40 minutes. The patient is then placed in the scanner where detectors are used to create a three-dimensional image of the tracer distribution.
Scans are reviewed and interpreted by a qualified imaging professional such as a nuclear medicine physician or radiologist who shares the results with the patient’s physician.
How is molecular neuroimaging used for Alzheimer’s disease?
Researchers are exploring the use of PET and SPECT to:
- help diagnose AD early in the disease process
- differentiate AD from other types of dementia
- monitor the progression of the disease
- determine the effectiveness of new therapies
- gain a better understanding of AD, including its causes and progression
What are the advantages of PET for the brain?
- PET allows metabolic activity to be directly visualized, not inferred.
- PET studies allow abnormal brain function to be detected before structural changes resulting from brain cell death can be seen on CT or MRI.
- PET is highly useful in detecting specific types of dementia, such as Alzheimer's disease and frontotemporal dementia. In these disorders, early brain damage may not impact brain volume or structure that is identifiable on CT or MR.
Is molecular neuroimaging covered by insurance?
Insurance companies will cover the cost of some PET scans. PET scans that measure brain amyloid plaques are covered if part of a clinical trial. Check with your insurance company for specific information on your plan. Not all procedures described herein are covered by every insurance plan.